RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.

Around 15-20% of primary breast cancers are characterized by HER2 protein overexpression and/or HER2 gene amplification. Despite the successful development of anti-HER2 drugs, intrinsic and acquired resistance represents a major hurdle. This study was performed to analyze the RANK pathway contributi...

Descripción completa

Detalles Bibliográficos
Autores: Sanz-Moreno, Adrián, Palomeras, Sonia, Pedersen, Kim, Morancho, Beatriz, Pascual, Tomas, Galván, Patricia, Benítez, Sandra, Gomez-Miragaya, Jorge, Ciscar, Marina, Jimenez, Maria, Pernas, Sonia, Petit, Anna, Soler-Monsó, María Teresa, Viñas, Gemma, Alsaleem, Mansour, Rakha, Emad A, Green, Andrew R, Santamaria, Patricia G, Mulder, Celine, Lemeer, Simone, Arribas, Joaquin, Prat, Aleix, Puig, Teresa, Gonzalez-Suarez, Eva
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/25176
Acceso en línea:https://hdl.handle.net/20.500.12105/25176
Access Level:acceso abierto
Palabra clave:Breast cancer
HER2
Lapatinib
NF-κB
RANK
RANKL
Resistance
Trastuzumab
Descripción
Sumario:Around 15-20% of primary breast cancers are characterized by HER2 protein overexpression and/or HER2 gene amplification. Despite the successful development of anti-HER2 drugs, intrinsic and acquired resistance represents a major hurdle. This study was performed to analyze the RANK pathway contribution in HER2-positive breast cancer and anti-HER2 therapy resistance.

Similares en LA Referencia